中國醫藥(600056.SH):聘任王宏新擔任公司總經理
格隆匯6月1日丨中國醫藥(600056.SH)公告,近日收到董事、總經理侯文玲的書面辭職報告。因工作調整原因,侯文玲申請辭去公司董事、總經理及董事會專門委員會相關職務,並將不再擔任公司任何職務。根據《公司章程》規定,侯文玲的辭職未造成公司董事人數低於法定人數,其辭職報告自送達董事會時生效。
根據《公司章程》相關規定,經公司控股股東推薦,董事會提名委員會審查合格,並經公司第八屆董事會第6次會議審議通過,董事會同意聘任王宏新擔任公司總經理職務,任期至本屆董事會屆滿。同時,董事會提名王宏新為公司董事候選人,該事項尚需提交公司股東大會審議通過。
王宏新,53歲,碩士,助理國際商務師。曾任公司綜合貿易部總經理、公司總經理助理、董事、副總經理。現任公司總經理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.